Status:
COMPLETED
Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
Lead Sponsor:
Vanderbilt University
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
A prospective, single center, open-label, randomized trial of Thymoglobulin induction and sirolimus, prednisone, and mycophenolate mofetil versus Thymoglobulin induction and tacrolimus, prednisone, an...
Detailed Description
Calcineurin inhibitor-associated nephrotoxicity may exacerbate chronic allograft nephropathy and reduce long-term kidney graft survival. Complete avoidance of calcineurin inhibitors may improve graft ...
Eligibility Criteria
Inclusion
- Primary cadaver or non-HLA identical living donor kidney transplant. -
Exclusion
- HIV HCV Pregnancy Age \< 18 years Malignancy
- \-
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00305396
Start Date
April 1 2004
End Date
March 1 2005
Last Update
March 21 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center/Nashville VA
Nashville, Tennessee, United States, 37232